Sun Pharmaceuticals Industries Ltd.


Top intraday trading ideas for afternoon trade for Tuesday 8 January News 08 Jan , Text Size A A A. Gaurav Ratnaparkhi Recos 22 Oct ,

Sun Pharmaceutical Industries Ltd.

Chandan Taparia Recos 30 Oct , More Sun Pharmaceutical Industries Ltd. Top intraday trading ideas for afternoon trade for Tuesday 8 January News 08 Jan , Sensex ends on a tepid note, Nifty inches up to 10, News 31 Dec , Sensex, Nifty log gains for 3rd day as bank stocks spurt News 28 Dec , Nifty reclaims 10, level; five key factors that fuelled the rally News 28 Dec , India Inc lost 39 billion-dollar babies in as the midcap mayhem singed News 28 Dec , Stocks in the news: Big jump in number of cases settled by Sebi in past 3 years News 26 Dec , Sensex, Nifty turn rangebound after positive start News 24 Dec , Sun Pharmaceutical Industries Announcements.

What's your view on Sun Pharmaceutical Industries for the week? Post as Guest New User? We will never share or display your Email. You will be notified, only if others like your post. Better performer than its peers on this ratio Average performer than its peers on this ratio Underperformer than its peers on this ratio.

Reliance Large Cap Direct-G. Kotak Equity Arbitrage Direct-G. About Sun Pharmaceutical Industries Ltd. To continue receiving alerts, please enter your email id below Enter email address. Add this company to your Watchlist. Cardiology products were introduced in followed by gastroenterology products in Today, it is the largest chronic prescription company in India and a market leader in psychiatry , neurology, cardiology, orthopedics , ophthalmology , gastroenterology and nephrology.

The acquisition of Ranbaxy has made the company the largest pharma company in India, the largest Indian pharma company in US, and the 5th largest specialty generic company globally. In US, the company markets a large basket of generics, with a strong pipeline awaiting approval from the U.

Sun Pharma was listed on the stock exchange in in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company. Today Sun Pharma is the second largest and the most profitable pharmaceutical company in India, as well as the largest pharmaceutical company by market capitalisation on the Indian exchanges. Sun Pharma has complemented growth with select acquisitions over the last two decades. Also in , Sun Pharma initiated their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in Detroit.

In , Sun acquired a number of respiratory brands from Natco Pharma. In , the company acquired a large stake in Taro Pharmaceuticals , [13] amongst the largest generic derma companies in US, with operations across Canada and Israel. In , Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets other than India.

In , Sun announced acquisitions of two US companies: Japan's Daiichi Sankyo held After this acquisition, Sun Pharma has become the largest pharmaceutical company in India, the largest Indian Pharma company in US, and the 5th largest generic company worldwide [19].

In March , Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business in Australia to strengthen its pain management portfolio. From Wikipedia, the free encyclopedia. The total volume of shares traded was 4. Sales on the other hand came in at Rs 69 bn up 4. Sales on the other hand came in at Rs 72 bn up Following a super investor can certainly help build a portfolio and create wealth in the long term.

As we began putting the pieces the pieces together, I noticed trends that were not seen in the past 5, 10, 15 and even 20 years. Richa dissects the common mistakes investors make and how to avoid and even take advantage of them. Since , Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day.

Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.